LBX Pharmacy Chain Future Growth

Future criteria checks 1/6

LBX Pharmacy Chain is forecast to grow earnings and revenue by 15.5% and 11.2% per annum respectively. EPS is expected to grow by 16.2% per annum. Return on equity is forecast to be 14.4% in 3 years.

Key information

15.5%

Earnings growth rate

16.2%

EPS growth rate

Consumer Retailing earnings growth	40.3%
Revenue growth rate	11.2%
Future return on equity	14.4%
Analyst coverage	Good
Last updated	21 Jan 2025

Recent future growth updates

Recent updates

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Dec 24

We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster Earnings

Nov 06

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Sep 06

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Sep 02

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Jul 03

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

Jun 08

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

May 21

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

Apr 22

Earnings and Revenue Growth Forecasts

SHSE:603883 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	33,516	1,301	2,771	N/A	1
12/31/2026	28,901	1,207	2,584	2,921	10
12/31/2025	25,930	1,067	2,379	2,740	11
12/31/2024	22,792	858	2,532	2,054	10
9/30/2024	22,628	843	1,855	2,556	N/A
6/30/2024	22,566	918	1,648	2,304	N/A
3/31/2024	22,536	959	1,741	2,298	N/A
12/31/2023	22,437	929	2,109	2,730	N/A
9/30/2023	22,441	892	1,500	1,841	N/A
6/30/2023	21,995	842	1,990	2,337	N/A
3/31/2023	21,475	835	2,558	2,903	N/A
12/31/2022	20,176	785	2,006	2,314	N/A
9/30/2022	18,192	746	2,201	2,530	N/A
6/30/2022	17,226	720	1,910	2,249	N/A
3/31/2022	16,198	683	1,586	2,112	N/A
12/31/2021	15,696	669	1,820	2,298	N/A
9/30/2021	15,128	666	1,654	2,082	N/A
6/30/2021	14,741	691	1,586	2,058	N/A
3/31/2021	14,323	653	1,362	1,693	N/A
12/31/2020	13,967	621	1,053	1,447	N/A
9/30/2020	13,413	602	919	1,362	N/A
6/30/2020	12,816	575	669	1,042	N/A
3/31/2020	12,218	545	634	1,036	N/A
12/31/2019	11,663	509	606	1,033	N/A
9/30/2019	11,069	505	423	1,033	N/A
6/30/2019	10,567	484	63	990	N/A
3/31/2019	9,988	464	1	883	N/A
12/31/2018	9,471	435	40	913	N/A
9/30/2018	9,015	421	-30	559	N/A
6/30/2018	8,484	401	N/A	568	N/A
3/31/2018	7,984	388	N/A	518	N/A
12/31/2017	7,501	371	N/A	498	N/A
9/30/2017	7,036	363	N/A	609	N/A
6/30/2017	6,780	343	N/A	413	N/A
3/31/2017	6,494	331	N/A	420	N/A
12/31/2016	6,094	297	N/A	313	N/A
9/30/2016	5,673	285	N/A	331	N/A
6/30/2016	5,250	265	N/A	280	N/A
3/31/2016	4,850	254	N/A	257	N/A
12/31/2015	4,568	241	N/A	257	N/A
9/30/2015	4,331	226	N/A	217	N/A
6/30/2015	4,178	218	N/A	276	N/A
3/31/2015	4,063	212	N/A	266	N/A
12/31/2014	3,943	202	N/A	247	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603883's forecast earnings growth (15.5% per year) is above the savings rate (2.8%).

Earnings vs Market: 603883's earnings (15.5% per year) are forecast to grow slower than the CN market (25% per year).

High Growth Earnings: 603883's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603883's revenue (11.2% per year) is forecast to grow slower than the CN market (13.3% per year).

High Growth Revenue: 603883's revenue (11.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603883's Return on Equity is forecast to be low in 3 years time (14.4%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/01 03:20
End of Day Share Price	2025/01/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LBX Pharmacy Chain Joint Stock Company is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yue Gao	Changjiang Securities Co. LTD.
Qianyi Li	China International Capital Corporation Limited
Bing Zhao	China Renaissance Securities

LBX Pharmacy Chain Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 13%

Price target decreased by 12% to CN¥26.64

Consensus EPS estimates fall by 29%

Price target increased by 8.1% to CN¥45.36

Price target increased by 7.5% to CN¥43.11

Price target increased to CN¥41.97

Recent updates

LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2024 Results on Apr 30, 2025

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Consensus EPS estimates increase by 13%

We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster Earnings

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥0.33 per share

LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024

Price target decreased by 12% to CN¥26.64

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates fall by 29%

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Now 23% undervalued after recent price drop

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Investor sentiment deteriorates as stock falls 17%

LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024

Dividend increased to CN¥0.66

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 18%

LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021)

Now 21% undervalued after recent price drop

Price target increased by 8.1% to CN¥45.36

Now 21% undervalued after recent price drop

Price target increased by 7.5% to CN¥43.11

Price target increased to CN¥41.97

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥58.58

Consensus EPS estimates fall by 21%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥63.49

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020)

LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion.

Price target decreased to CN¥75.25

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020)

Price target decreased to CN¥79.67

Price target decreased to CN¥86.50

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020)

New 90-day low: CN¥61.85

New 90-day high: CN¥81.64

Investor sentiment improved over the past week

New 90-day low: CN¥63.60

New 90-day low: CN¥65.89

New 90-day low: CN¥67.21

Price target raised to CN¥97.98

Laobaixing Reportedly in Merger Talks with Yixintang

Third quarter earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020

Price target raised to CN¥89.75

New 90-day high - CN¥87.00

New 90-day high - CN¥87.00

First half earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020

Earnings and Revenue Growth Forecasts